NCI-H2195 Cells

The NCI-H2195 cell line is derived from human lung small cell carcinoma (SCLC). Specifically, this cell line was established from the bone marrow metastasis of an adult patient with lung small cell carcinoma. NCI-H2195 cells are characterized by their epithelial morphology and their ability to grow adherently in culture. They exhibit typical features of SCLC, including the presence of neuroendocrine markers and genetic mutations commonly associated with this aggressive form of lung cancer. NCI-H2195 cells are extensively used in cancer research to study the molecular and cellular mechanisms of small cell lung carcinoma. This includes investigations into the pathways involved in tumor growth, metastasis, and response to therapy. Researchers utilize this cell line to explore the effects of chemotherapeutic agents, targeted therapies, and novel treatment strategies on SCLC. The NCI-H2195 cell line is particularly valuable for studying the genetic and epigenetic alterations that drive SCLC, such as mutations in TP53, RB1, and MYC, which are frequently observed in this type of cancer. In addition, the NCI-H2195 cell line serves as a model for preclinical studies aimed at identifying biomarkers for early detection, prognosis, and therapeutic response in small cell lung carcinoma. By providing a reliable in vitro system, this cell line contributes to the development of more effective treatments and a better understanding of the disease, ultimately aiding in the advancement of personalized medicine approaches for SCLC patients.